N/A N=12 Aspirin and Compression Devices for VTE Prophylaxis in Orthopaedic Oncology
Bone Metastases · Musculoskeletal Cancer · Soft Tissue Sarcoma
Primary: DVT Incident Rate — 0; 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=925 Efficacy and Safety of CIP-Isotretinoin in Patients With Severe Recalcitrant Nodular Acne
Severe Nodular Acne
Primary: Co-primary Outcome 1: Change From Baseline in Total Nodular Lesion Count (Facial and Truncal) — -17.01; -16.52 Lesions — p=0.5077
Phase 2 N=25 Low Dose IL-2, Hematopoietic Stem Cell Transplantation, IL2 for GVHD
Acute Lymphoblastic Leukemia · ALL · Acute Myelogenous Leukemia
Primary: Rate of Dose Limiting Toxicities — 0.045 proportion of participants of DLT
Phase 1 N=48 Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Doses of BI 10773 Tablets
Diabetes Mellitus, Type 2
Primary: Percentage of Participants With Clinically Relevant Findings in Physical Examination, Vital Signs and Clinical Laboratory Tests — 0.0; 0.0; 0.0; 0.0 percentage of…
Phase 1 N=24 Zoledronic Acid and Combination Chemotherapy in Treating Patients With Newly Diagnosed Metastatic Osteosarcoma
Sarcoma
Primary: Limiting Toxicity — 1; 1; 3; 2 participants
Phase 2 N=100 Intravaginal LACTIN-V for Prevention of Recurrent Urinary Tract Infection
Urinary Tract Infection
Primary: Incidence of Urinary Tract Infection — 7; 13 participants
Phase 4 N=117 Belotero Post Approval Study
Nasolabial Folds
Primary: Rate of Severe Common Adverse Events — 8.5 percentage of 'severe' common AEs — p=< 0.025
N/A N=25 TriActive+ Radiofrequency (RF) for Non-invasive Treatment of Wrinkles & Rhytides
Wrinkles · Rhytides
Primary: Fitzpatrick Classification of Wrinkling and Degree of Elastosis. — 5.6; 5.56; 5.36; 5.32 Fitzpatrick Classification Scale
Phase 3 N=55 Memantine as a Supplement to Naltrexone in Treating Heroin Dependence
Opioid Dependence · Heroin Dependence
Primary: Opiate Use Measured by Urine Toxicology Results — 9; 10 Percent of total urine samples
Phase 3 N=300 Phase3 Study of Amrubicin With Cisplatin Versus Etoposide-cisplatin for Extensive Disease Small Cell Lung Cancer
Lung Cancer
Primary: Overall Survival — 11.79; 10.28 month
N/A N=40 Fat Perception in Humans (09-0873)
Obesity
Primary: Oleic Acid Detection Level — -0.3; -1.2; -1.0 log10 (%W/V OLEIC ACID) — p=0.05
Phase 1 N=20 Open-label Leucovorin Pharmacokinetic Study in Patients Receiving High Dose Methotrexate With or Without Voraxaze
Osteosarcoma · Leukemia · Lymphoma
Primary: Pharmacokinetics (PK) of Leucovorin — 6.43; 1.13 micromol x hour/L
Phase 4 N=109 Effect of Bisphosphonate on Bone Loss in Postmenopausal Women With Breast Cancer Initiating Aromatase Inhibitor Therapy
Bone Loss · Osteoporosis · Breast Cancer
Primary: BMD of Spine by DXA — 2.269; -1.735 percentage change
Phase 2 N=83 Efficacy and Safety of Ranibizumab (Intravitreal Injections) Versus Laser Treatment in Patients With Visual Impairment Due to Diabetic Macular Edema
Diabetic Macular Edema · Visual Impairment
Primary: Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) — 9.41; 5.79 letters
Phase 3 N=784 Efficacy and Long-Term Safety of Ragweed (Ambrosia Artemisiifolia) Sublingual Tablet (SCH 39641) in Adults With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (Study P05234)
Rhinitis, Allergic · Conjunctivitis
Primary: Combined (Sum of) Rhinoconjunctivitis Daily Symptom Score (DSS) and Daily Medication Score (DMS) Averaged Over the Peak Ragweed Season (RS) — 7.70; 6.88; 6.41; 8.46…